Listed

Carlisle Companies Inc: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Oct 22, 2020 and accepted by EDGAR at Oct 22, 2020, 13:44 ET.

Share

Management's discussion and analysis

As filed, 59,265 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Carlisle Companies Incorporated ("Carlisle", the "Company", "we", "us" or "our") is a diversified, global portfolio of niche businesses that manufactures highly engineered products and solutions for its customers. Driven by our strategic plan, Vision 2025, Carlisle is committed to generating superior shareholder returns by combining an entrepreneurial management style under a center-led approach, and balanced capital deployment, all with a culture of responsible stewardship and continuous improvement as embodied in the Carlisle Operating System ("COS"). Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with a narrative from the perspective of Company management. All references to "Notes" refer to our Notes to Condensed Consolidated Financial Statements in Item 1 of this quarterly report on Form 10-Q.

Executive Overview

While the coronavirus pandemic ("COVID-19") has affected our near-term results, we believe our proactive approach will allow us to accelerate through the recovery by: further improving the efficiency of our businesses through COS, continuing to make the investments necessary to deliver a world-class Carlisle Experience, and ensuring we maintain discipline and rigor in our capital allocation process. Taken together, we believe these actions will drive us to achieve our goals outlined in Vision 2025.

Third quarter results were led again by Carlisle Construction Materials ("CCM"), which delivered a 5% year-over-year improvement in operating income despite an 8% decline in revenue. Notably, there was sequential improvement through the third quarter with September sales ending slightly positive year-over-year for the first time since the pandemic began. At Carlisle Interconnect Technologies ("CIT"), we continue to experience the effects of a record global decline in commercial aerospace production and the accompanying ripple effects through the supply chain. That said, we do see signs of an improving outlook and believe we are nearing the low point in our aerospace business and approaching a slow but meaningful recovery. CIT's medical technologies platform continued to have a positive impact in the third quarter driven by robust demand for COVID-19 related patient monitoring equipment, which was partially offset by the reduction in elective surgeries and hospital capital spending. Carlisle Fluid Technologies ('CFT") delivered positive sequential results, despite being highly exposed to pandemic effects. Operating income improved 5% year-over-year driven by positive price realization, improved operational execution and new product introductions, including our recently launched market differentiated fluid handling system for spray foam, in spite of a sales decline of 5% year-over-year. Carlisle Brake & Friction ("CBF") delivered significantly improved sales results sequentially, down 9% in the third quarter compared to down over 30% in the second quarter of 2020. Given the actions taken over the past several years, its strong market position, and traction on new technology introductions, we expect CBF to benefit favorably from any improvements in volume as its markets recover post-pandemic.

As always, we remain very focused on maintaining our financial and strategic flexibility to be able to best leverage future opportunities. During the first nine months of 2020, we demonstrated this strength by repurchasing 2.7 million shares for $341.7 million, paying our dividend of $84.7 million, deploying $72.7 million into capital expenditures and investing $42.2 million into research and development. As of the end of the third quarter, we have a strong cash position of $719.0 million with $1.0 billion undrawn on our revolving credit facility (the "Facility").

We enter the fourth quarter of 2020 confident in our ability to accelerate though the recovery that we are starting to see in our businesses and deliver on Vision 2025. Uncertainties remain regarding the length and severity of the global economic slowdown attributable to COVID-19, continued tension with China and volatility surrounding the upcoming elections in the United States that will likely result in a choppy path to ultimate recovery, and we are unable to predict the full impact or duration of these events on Carlisle at this time. However, given our strong balance sheet and cash flow generating capabilities, we believe we are well prepared to navigate the future while maintaining our disciplined and opportunistic capital deployment strategy.

Summary of Financial Results

(in millions, except per share amounts)

Three Months Ended September 30, 2020 2019 Nine Months Ended September 30, 2020 2019
Revenues $1,126.7 $1,280.6 $3,181.1 $3,667.3
Operating income $155.7 $191.0 $371.8 $512.9
Operating margin percentage 13.8% 14.9% 11.7% 14.0%
Income from continuing operations $102.3 $139.3 $239.5 $369.7
(Loss) income from discontinued operations $— $(1.4) $— $0.5
Diluted earnings per share attributable to common shares:
Income from continuing operations $1.87 $2.42 $4.31 $6.40
(Loss) income from discontinued operations $— $(0.02) $— $0.01
Items affecting comparability:(1)
Impact to operating income $6.3 $7.4 $33.9 $19.1
Impact to income from continuing operations $4.0 $3.9 $29.1 $6.8
Impact on diluted EPS from continuing operations $0.07 $0.07 $0.52 $0.12

(1) Items affecting comparability primarily include acquisition related costs, exit and disposal costs, facility rationalization costs, litigation settlement costs, gains from divestitures, idle capacity and labor costs, net of subsidies, losses on debt extinguishment and discrete tax items. Tax effect is based on the rate of the jurisdiction where the expense is deductible. Refer to Items Affecting Comparability in this MD&A for further information.

Revenues decreased in the 2020 periods primarily reflecting lower volumes in all of our segments, which have continued to be impacted by the global economic slowdown due to COVID-19. Contributions from acquisitions, primarily Providien, LLC ("Providien"), partially offset the decrease in volume.

The decrease in operating income in the 2020 periods primarily reflected lower volumes as well as lower production levels increasing per unit costs and wage inflation. The decrease in operating income was partially offset by raw material savings, particularly in our CCM segment, lower incentive compensation and travel costs, and savings from COS.

Diluted earnings per share from continuing operations decreased primarily from the above operating income performance ($0.47 per share in the third quarter of 2020 and $1.87 per share in the first nine months of 2020), higher interest expense ($0.03 per share in the third quarter of 2020 and $0.11 per share in the first nine months of 2020) and a higher effective tax rate ($0.06 per share in the third quarter of 2020 and $0.09 per share in the first nine months of 2020). The decrease was partially offset by reduced average shares outstanding ($0.09 per share in the third quarter of 2020 and $0.17 per share in the first nine months of 2020) resulting from our share repurchase program.

We generated $440.2 million in operating cash flow in the first nine months of 2020, and utilized cash on hand and cash provided by operations to return capital to shareholders through dividends and share repurchases, and fund capital expenditures.

Consolidated Results of Operations

Revenues

(in millions)

2020 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Three months ended September 30 $1,126.7 $1,280.6 $(153.9) (12.0)% 1.9% (14.3)% 0.4%
Nine months ended September 30 $3,181.1 $3,667.3 $(486.2) (13.3)% 2.3% (15.5)% (0.1)%

The decrease in revenues in the 2020 periods primarily reflected lower sales volumes in all segments, which continue to be impacted by the global economic slowdown due to COVID-19. CIT volume decline was led by lower sales in the commercial aerospace market, and CCM, CBF and CFT experienced declines in sales volumes across all markets in which they operate. Partially offsetting the decline was contribution of $20.1 million in the third quarter and $65.2 million in the first nine months of 2020 from the acquisition of Providien in the CIT segment.

Gross Margin

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Gross margin $330.3 $380.2 $(49.9) (13.1)% $889.9 $1,063.0 $(173.1) (16.3)%
Gross margin percentage 29.3% 29.7% 28.0% 29.0%
Depreciation and amortization $30.3 $24.6 $91.7 $71.7

Gross margin percentage (gross margin expressed as a percentage of revenues) declined in the 2020 periods, driven by lower sales volume in all segments, as well as lower production levels increasing per unit costs and wage inflation, partially offset by favorable raw material pricing and purchase savings from COS. Also included in cost of goods sold were exit and disposal costs totaling $3.7 million for the third quarter and $9.8 million for the first nine months of 2020, primarily at CIT, attributable to our restructuring initiatives, compared with $1.2 million for the third quarter and $5.7 million for the first nine months of 2019. Refer to Note 8 for further information on exit and disposal activities.

Selling and Administrative Expenses

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Selling and administrative expenses $162.3 $175.0 $(12.7) (7.3)% $477.3 $511.5 $(34.2) (6.7)%
As a percentage of revenues 14.4% 13.7% 15.0% 13.9%
Depreciation and amortization $25.3 $26.3 $75.4 $78.3

The decrease in selling and administrative expenses in the 2020 periods primarily reflected lower incentive compensation and travel costs, and lower medical costs. The decreases were partially offset by wage inflation and higher legal and consulting costs, and in the nine month period, termination costs associated with the expiration of the agreement to acquire Draka Fileca SAS. Also included in selling and administrative expenses were exit and disposal costs totaling $1.6 million for the third quarter and $6.8 million for the first nine months of 2020, primarily at CBF, CFT and CIT, attributable to our restructuring initiatives, compared with $0.6 million for the third quarter and $4.1 million for the first nine months of 2019. Refer to Note 8 for further information on exit and disposal activities.

Research and Development Expenses

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Research and development expenses $13.7 $15.2 $(1.5) (9.9)% $42.2 $45.0 $(2.8) (6.2)%
As a percentage of revenues 1.2% 1.2% 1.3% 1.2%
Depreciation and amortization $0.6 $0.4 $1.9 $1.4

Research and development expenses were lower in the 2020 periods, compared with the 2019 periods, primarily reflecting lower new product development expenses at our CIT and CFT segments.

Other Operating Income, net

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Other operating income, net $(1.4) $(1.0) $(0.4) 40.0% $(1.4) $(6.4) $5.0 (78.1)%

Other operating income, net in the third quarter of 2020 primarily reflected $0.9 million of rebates and $0.3 million of royalty income, partially offset by $0.5 million of losses on sale of assets, primarily at CCM. Other operating income, net in the first nine months of 2020 primarily reflected $2.1 million of rebates, $1.1 million of rental income and $1.0 million of royalty income, partially offset by $3.4 million of losses on sale of assets, primarily at CCM, CBF and CIT.

Other operating income, net in the first nine months of 2019 primarily reflected a $3.0 million gain on contingent consideration at CFT, $1.8 million of rebates and $0.5 million of gains on sales of assets, primarily at CBF.

Operating Income

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Operating income $155.7 $191.0 $(35.3) (18.5)% $371.8 $512.9 $(141.1) (27.5)%
Operating margin percentage 13.8% 14.9% 11.7% 14.0%

Refer to Segment Results of Operations within this MD&A for further information related to segment operating income results.

Interest Expense, net

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Interest expense, net $19.0 $16.7 $2.3 13.8% $57.7 $49.6 $8.1 16.3%

Interest expense, net of capitalized interest, during the 2020 periods primarily reflected higher long-term debt balances associated with our public offering of $750.0 million of 2.75% unsecured senior notes completed in February 2020, and draws on our Facility in the first quarter of 2020, which were repaid in the second quarter of 2020. Refer to Note 12 for further information on our long-term debt.

Loss on Extinguishment of Debt

Loss on extinguishment of debt related to the early redemption in full of our $250.0 million aggregate principal amount of our outstanding 5.125% notes due December 15, 2020 (the “2020 Notes”). The 2020 Notes were redeemed on March 29, 2020 at the redemption price of $262.1 million. The redemption price included a premium of $8.4 million, along with $0.4 million of deferred issuance costs and resulted in a loss of $8.8 million. Refer to Note 12 for further discussion.

Interest Income

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Interest income $(0.6) $(1.7) $1.1 (64.7)% $(4.0) $(6.2) $2.2 (35.5)%

Interest income decreased during the 2020 periods primarily related to lower yields.

Other Non-operating Expense (Income), net

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Other non-operating expense (income), net $0.9 $(1.2) $2.1 (175.0)% $(0.3) $(2.2) $1.9 (86.4)%

Other non-operating expense (income), net in the third quarter of 2020 primarily reflected changes in foreign currencies against the U.S. Dollar. Other non-operating expense (income), net in the first nine months of 2020 primarily reflected foreign exchange gains from the strengthening of the U.S. Dollar, partially offset by the release of a portion of the indemnification asset related to the Petersen acquisition resulting from escrow expirations.

Other non-operating expense (income), net in the 2019 periods primarily reflected foreign exchange gains from the strengthening of the U.S. Dollar.

Income Taxes

(in millions)

2020 Three Months Ended September 30, 2019 Change% 2020 Nine Months Ended September 30, 2019 Change%
Provision for income taxes $34.1 $37.9 $(3.8) (10.0)% $70.1 $102.0 $(31.9) (31.3)%
Effective tax rate 25.0% 21.4% 22.6% 21.6%

The effective income tax rate on continuing operations for the first nine months of 2020 was 22.6%. The year-to-date provision for income taxes included taxes on earnings at an anticipated rate of 24.6% and a tax impact of

$6.1 million related to discrete activity. The year-to-date net discrete tax benefit relates primarily to a reduction of unrecognized income tax benefits.

The effective income tax rate on continuing operations for the first nine months of 2019 was 21.6%.

(Loss) Income from Discontinued Operations

Loss from discontinued operations of $1.4 million in the third quarter of 2019 relates to an environmental remediation accrual associated with Motion Control Industries, Inc., which was disposed of in 2009. Income from discontinued operations of $0.5 million for the first nine months of 2019 reflects the above noted loss, completely offset by the settlement of prior income tax positions in the current year, related to the sale of Carlisle FoodService Products.

Segment Results of Operations

We continue to operate our facilities as essential business operations, while adhering to all health and safety measures for onsite employees. We have taken several steps to address the overall effects of COVID-19 on Carlisle and continue to assess the risks and potential impacts on our businesses. We have developed plans and implemented actions to mitigate risks and enhance the performance of our businesses in an uncertain environment dependent largely on future developments, which are highly uncertain and cannot be predicted.

Carlisle Construction Materials ("CCM")

CCM delivered a 5% year-over-year improvement in operating income despite an 8% decline in revenue. Notably, there was sequential improvement through the third quarter with September sales ending slightly positive year-over-year for the first time since the pandemic began. We believe recently announced price increases by the major CCM competitors and improving demand trends in the industry are positive signs as we move into the fourth quarter and 2021. These positive signs are coupled with significant long-term positive re-roofing projections, CCM's consistent price leadership, efficiencies gained from COS and our ability to deliver world-class service through the Carlisle Experience. When taken with the sequential improvements in the third quarter in sales, we are cautiously optimistic about the fourth quarter and early 2021.

(in millions)

2020 Three Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $823.5 $893.5 $(70.0) (7.8)% —% (8.1)% 0.3%
Operating income $181.3 $173.0 $8.3 4.8%
Operating margin percentage 22.0% 19.4%
Depreciation and amortization $24.4 $23.4
Items affecting comparability(1) $1.3 $0.8

(1) Items affecting comparability include exit and disposal and facility rationalization costs of $0.6 million, idle capacity and labor costs, net of subsidies, of $0.5 million, and acquisition-related costs of $0.2 million in the third quarter of 2020 and acquisition-related costs of $0.8 million in the third quarter of 2019. Refer to Items Affecting Comparability below.

CCM’s revenue decline in the third quarter of 2020 primarily reflected lower volumes across all of our product lines due to delays in customer demand and in new construction projects attributable to COVID-19.

CCM’s operating margin percentage increase in the third quarter of 2020 primarily reflected favorable raw material pricing, particularly methylene diphenyl diisocyanate ("MDI"), lower travel and other administrative costs and savings from COS, partially offset by lower volumes and wage inflation.

(in millions)

2020 Nine Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $2,234.8 $2,479.6 $(244.8) (9.9)% 0.1% (10.0)% —%
Operating income $426.6 $448.4 $(21.8) (4.9)%
Operating margin percentage 19.1% 18.1%
Depreciation and amortization $74.2 $69.2
Items affecting comparability(1) $3.2 $2.6

(1) Items affecting comparability include idle capacity and labor costs, net of subsidies, of $2.7 million, exit and disposal and facility rationalization costs of $0.9 million, acquisition related costs of $0.4 million, and $(0.8) million from the sale of a business during the first nine months of 2020, and acquisition related costs of $2.4 million and exit and disposal and facility rationalization costs of $0.2 million in the first nine months of 2019. Refer to Items Affecting Comparability below.

CCM’s revenue decline in the first nine months of 2020 primarily reflected lower volumes across all of our product lines due to delays in customer demand and in new construction projects attributable to COVID-19.

CCM’s operating margin percentage increase in the first nine months of 2020 was driven by favorable raw material pricing, lower travel and administrative costs and savings from COS, and offset by lower volumes and wage inflation.

Carlisle Interconnect Technologies ("CIT")

At CIT, we continue to experience the effects of a record global decline in commercial aerospace production and the accompanying ripple effects through the supply chain. That said, we do see signs of an improving outlook. Some positive news include, the European regulatory body has approved the 737 Max-8 aircraft for return to flying; Airbus announced in early October that it had delivered 57 aircraft in September, up from an April low of 14; Boeing has had very few cancellations in recent weeks and daily Transportation Security Administration ("TSA") screenings reached over one million passengers per day on October 18, 2020, for the first time since March. With all these positives, we feel we are nearing the low point in our aerospace business and approaching a slow but meaningful recovery.

CIT's medical technologies platform continued to have a positive impact in the third quarter driven by robust demand for COVID-19 related patient monitoring equipment, which was partially offset by the reduction in elective surgeries and hospital capital spending. We continue to seek opportunistic acquisition opportunities to complement our existing product suite, driving to an improved balance of market exposures at CIT.

In August 2020, as a result of the market declines caused by COVID-19, we announced the closure of our manufacturing operations in Kent, Washington, and the relocation of selected operations to our existing facilities primarily in North America. This project is estimated to take 12 to 18 months to complete. Total project costs are expected to approximate $18.9 million, with approximately $15.5 million remaining to be incurred.

In April 2020, we announced plans to exit our manufacturing operations in Mobile, Alabama, and relocate the majority of those operations to CIT's existing manufacturing facility in Franklin, Wisconsin. This project is substantially complete with cumulative costs of $1.6 million recognized through September 30, 2020.

In January 2019, we announced the relocation of our connectors manufacturing operations in El Segundo, California, and Riverside, California, to our existing lower cost facilities in North America. This project is complete with cumulative costs of $20.8 million recognized through September 30, 2020. Refer to Note 8 for further information regarding exit and disposal activities.

(in millions)

2020 Three Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $168.5 $241.9 $(73.4) (30.3)% 8.8% (39.1)% —%
Operating (loss) income $(3.7) $36.0 $(39.7) (110.3)%
Operating margin percentage (2.2)% 14.9%
Depreciation and amortization $19.6 $15.7
Items affecting comparability(1) $4.5 $2.5

(1) Items affecting comparability include exit and disposal and facility rationalization costs of $4.6 million and acquisition costs of $0.1 million, partially offset by idle capacity and labor costs, net of subsidies, of $(0.2) million and in the third quarter of 2020. Items affecting comparability include exit and disposal and facility rationalization costs of $2.5 million in the third quarter of 2019. Refer to Items Affecting Comparability below.

CIT's revenue decline in the third quarter of 2020 primarily reflected lower volumes, led by the downturn in the commercial aerospace market as a result of continued delays in the 737 Max production and lower build rates on narrow and wide body aircraft by original equipment manufacturers ("OEMs") given steep declines in airline travel. The decline was partially offset by acquired medical device product lines.

CIT’s operating margin percentage decreased in the third quarter of 2020, driven by lower volumes, unfavorable mix, higher restructuring costs and wage and raw material inflation, partially offset by savings from COS and lower travel and other administrative costs.

(in millions)

2020 Nine Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $577.0 $733.7 $(156.7) (21.4)% 9.4% (30.7)% (0.1)%
Operating income $11.2 $102.5 $(91.3) (89.1)%
Operating margin percentage 1.9% 14.0%
Depreciation and amortization $58.4 $45.9
Items affecting comparability(1) $17.2 $9.8

(1) Items affecting comparability include exit and disposal and facility rationalization costs of $13.0 million, idle capacity and labor costs, net of subsidies, of $4.1 million, and acquisition related costs of $0.1 million in the first nine months of 2020. Items affecting comparability include exit and disposal and facility rationalization costs of $9.0 million and acquisition related costs of $0.8 million in the first nine months of 2019. Refer to Items Affecting Comparability below.

CIT's revenue decline in the first nine months of 2020 primarily reflected lower volumes, led by the commercial aerospace market as a result of continued delays in the 737 Max production and lower build rates on narrow and wide body aircraft by OEMs given steep declines in airline travel and customer plant shutdowns. The decline was partially offset by acquired medical device product lines.

CIT’s operating margin percentage decreased in the first nine months of 2020, driven by lower volumes, higher restructuring and facility rationalization costs, wage and raw material inflation, and unfavorable mix, partially offset by savings from COS and lower travel and other administrative costs.

Carlisle Fluid Technologies ("CFT")

CFT delivered positive sequential results despite being highly exposed to pandemic effects. Operating income improved 5% year-over-year driven by positive price realization, improved operational execution and new product introductions, including our recently launched market differentiated fluid handling system for spray foam, in spite of a sales decline of 5% year-over-year. We expect this positive trend of sequential growth to continue as we move through the fourth quarter. The team is executing and gaining traction on initiatives to improve quality and delivery to enhance our customers' experience. We believe the multitude of actions will continue to drive performance as we move into early 2021.

(in millions)

2020 Three Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $65.0 $68.5 $(3.5) (5.1)% 4.4% (10.8)% 1.3%
Operating income $4.4 $4.2 $0.2 4.8%
Operating margin percentage 6.8% 6.1%
Depreciation and amortization $5.8 $6.2
Items affecting comparability(1) $0.1 $1.0

(1) Items affecting comparability include acquisition related costs of $0.2 million, partially offset by idle capacity and labor costs, net of subsidies, of $(0.1) million in the third quarter of 2020 and acquisition related costs of $1.0 million in the third quarter of 2019. Refer to Items Affecting Comparability below.

CFT's revenue decrease in the third quarter of 2020 reflected volume declines due to COVID-19, particularly in the transportation end market, partially offset by contributions from acquisitions and price realization.

CFT’s operating margin percentage performance improved for the third quarter of 2020, reflecting lower travel and other administrative costs, price realization and savings from COS, partly offset by lower volumes and wage and raw material inflation.

(in millions)

2020 Nine Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $169.8 $198.9 $(29.1) (14.6)% 6.8% (21.3)% (0.1)%
Operating income $2.0 $13.9 $(11.9) (85.6)%
Operating margin percentage 1.2% 7.0%
Depreciation and amortization $17.4 $17.9
Items affecting comparability(1) $2.5 $1.4

(1) Items affecting comparability include exit and disposal and facility rationalization costs of $2.1 million and acquisition related costs of $0.4 million in the third quarter of 2020. Items affecting comparability also include exit and disposal and facility rationalization costs of $2.1 million, acquisition related costs of $2.3 million and a gain on contingent consideration of $(3.0) million in the third quarter of 2019. Refer to Items Affecting Comparability below.

CFT's revenue decrease in the first nine months of 2020 reflected volume declines due to COVID-19, particularly in the industrial and transportation end markets, partially offset by contributions from acquisitions and price realization.

CFT’s operating margin percentage performance for the first nine months of 2020 declined, reflecting lower volumes, and wage and raw material inflation, partially offset by lower travel and other administrative costs, savings from COS and price realization.

Carlisle Brake & Friction ("CBF")

CBF delivered significantly improved revenue results sequentially, down 9% in the third quarter compared to down over 30% in the second quarter of 2020. Market conditions are stabilizing but the demand for global off-highway vehicle markets is still weak. Another contributing factor to CBF's results is its exposure to the contracted aerospace industry where it supplies high margin metallic and carbon aircraft braking products. Given the actions taken over the past several years, its strong market position, and traction on new technology introductions, we expect CBF to benefit favorably from any improvements in volume as its markets recover post-pandemic.

During the first quarter of 2020, we initiated plans to consolidate certain operations globally to reduce costs and streamline processes by consolidating certain positions within selling, general and administrative, and manufacturing functions and exited less profitable product lines that resulted in asset write-offs. The project is estimated to take 9 to 12 months to complete. Total associated costs are expected to approximate $6.2 million, with approximately $1.6 million of costs remaining to be incurred, primarily in 2020.

(in millions)

2020 Three Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $69.7 $76.7 $(7.0) (9.1)% —% (10.8)% 1.7%
Operating income $0.9 $5.7 $(4.8) (84.2)%
Operating margin percentage 1.3% 7.4%
Depreciation and amortization $5.4 $5.3
Items affecting comparability(1) $0.4 $0.5

(1) Items affecting comparability include exit and disposal and facility rationalization costs $0.4 million in the third quarter of 2020 and $0.5 million in the third quarter of 2019. Refer to Items Affecting Comparability below.

CBF's revenue decrease in the third quarter of 2020 reflected difficult year-over-year volume comparisons as a result of declines in demand due to plant closures from COVID-19 in the heavy equipment and aerospace markets.

CBF's operating margin percentage decrease in the third quarter of 2020 was driven by lower volumes, unfavorable mix, and wage inflation, partially offset by savings from COS.

(in millions)

2020 Nine Months Ended September 30, 2019 Change% Acquisition Effect Price / Volume Effect Exchange Rate Effect
Revenues $199.5 $255.1 $(55.6) (21.8)% —% (21.3)% (0.5)%
Operating (loss) income $(4.5) $20.5 $(25.0) (122.0)%
Operating margin percentage (2.3)% 8.0%
Depreciation and amortization $16.3 $16.2
Items affecting comparability(1) $5.8 $2.3

(1) Items affecting comparability include idle capacity and labor costs, net of subsidies, of $1.2 million and exit and disposal and facility rationalization costs of $4.6 million in the first nine months of 2020 and $2.3 million in the first nine months of 2019. Refer to Items Affecting Comparability below.

CBF's revenue decrease in the first nine months of 2020 reflected difficult year-over-year volume comparisons as a result of declines in demand due to plant closures from COVID-19 in the heavy equipment, transportation and aerospace markets and foreign currency headwinds.

CBF's operating margin percentage decrease in the first nine months of 2020 was driven by lower volumes, higher restructuring and facility rationalization costs, unfavorable mix and wage inflation, partially offset by savings from COS.

Liquidity and Capital Resources

A summary of our cash and cash equivalents by region follows:

(in millions)

September 30, 2020 December 31, 2019
Europe $157.7 $62.2
North America (excluding U.S.) 34.2 43.4
China 39.8 17.9
Asia Pacific (excluding China) 38.0 69.1
International cash and cash equivalents 269.7 192.6
U.S. cash and cash equivalents 449.3 158.6
Total cash and cash equivalents $719.0 $351.2

We maintain liquidity sources primarily consisting of cash and cash equivalents as well as availability under our Facility. In the near term, cash on hand is our primary source of liquidity. The increase in cash and cash equivalents compared to December 31, 2019, was primarily related to proceeds from our public offering of $750.0 million of unsecured senior notes due in March 2030, partially offset by the early redemption of our $250.0 million notes due in December 2020. Additionally, during the first nine months of 2020, we utilized cash on hand to fund share repurchases, capital expenditures and pay dividends to shareholders.

In certain countries, primarily China, our cash is subject to local laws and regulations that require government approval for conversion of such cash to U.S. Dollars, as well as for transfer of such cash, both temporarily and permanently outside of that jurisdiction. In addition, upon permanent transfer of cash outside of certain jurisdictions, primarily in China, we may be subject to withholding taxes and as such we have accrued approximately $15 million in anticipation of those taxes as of September 30, 2020.

Despite the continued uncertainty in global markets resulting from COVID-19, we believe we have sufficient cash on hand, availability under the Facility and operating cash flows to meet our business requirements for at least the next 12 months. At the discretion of management, the Company may use available cash on capital expenditures, dividends, common stock repurchases, acquisitions and strategic investments.

We also anticipate we will have sufficient cash on hand, as well as available liquidity under the Facility, to pay outstanding principal balances of our existing notes by the respective maturity dates. Another potential source of liquidity is access to public capital markets, subject to market conditions. We may access the capital markets to repay the outstanding balance, if our sources of liquidity have been used for other strategic purposes by the time of maturity. Refer to Debt Instruments below.

Sources and Uses of Cash and Cash Equivalents

(in millions)

Nine Months Ended September 30, 2020 2019
Net cash provided by operating activities $440.2 $489.5
Net cash used in investing activities (106.7) (342.1)
Net cash provided by (used in) financing activities 36.7 (291.7)
Effect of foreign currency exchange rate changes on cash (2.4) (1.2)
Change in cash and cash equivalents $367.8 $(145.5)

Operating Activities

We generated operating cash flows of $440.2 million for the first nine months of 2020 (including working capital uses of $26.5 million), compared with $489.5 million for the first nine months of 2019 (including working capital uses of $62.9 million). Lower operating cash flows in the first nine months of 2020 primarily reflect lower cash earnings from decline in volumes, partially offset by a decline in net working capital as a result of decline in sales volumes as well as lower raw material costs at CCM.

Investing Activities

Cash used in investing activities of $106.7 million for the first nine months of 2020 primarily reflected capital expenditures of $72.7 million and the acquisition of Motion Tech Automation, LLC ("MTA"), net of cash acquired, for $33.0 million. Cash used in investing activities of $342.1 million for the first nine months of 2019 primarily reflected the acquisitions of Petersen, net of cash acquired, for $202.0 million, MicroConnex, net of cash acquired, for $45.4 million and other acquisitions, net of cash acquired, for $40.3 million, and capital expenditures of $56.6 million.

Financing Activities

Cash provided by financing activities was $36.7 million in the first nine months of 2020. Net proceeds from our February notes offering, partially offset by the early redemption of our senior notes due December 15, 2020, and financing costs associated with our February notes offering, totaled $458.0 million. Additionally, we used cash of $341.7 million for share repurchases and $84.5 million for cash dividend payments, reflecting the increased dividend of $1.525 per share. Cash used in financing activities of $291.7 million during the first nine months of 2019 primarily reflected $232.1 million of share repurchases and $74.5 million of dividend payments.

Debt Instruments

Senior Notes

On February 28, 2020, the Company completed a public offering of $750.0 million of unsecured senior notes with a stated interest rate of 2.75% due March 1, 2030 (the “2030 Notes”). The 2030 Notes were issued at a discount of $9.3 million, resulting in proceeds to the Company of $740.7 million. The Company incurred costs to issue the 2030 Notes of approximately $6.5 million, inclusive of underwriters’, credit rating agencies’ and attorneys’ fees, loss on treasury locks contract and other costs. The discount, issuance costs and loss on treasury locks are amortized to interest expense over the life of the 2030 Notes. Interest is payable each March 1 and September 1, commenced on September 1, 2020.

On February 28, 2020, we issued a notice for the redemption in full of our $250.0 million aggregate principal amount of its outstanding 5.125% notes due December 15, 2020 (the “2020 Notes”). The 2020 Notes were redeemed on March 29, 2020 at the redemption price of $262.1 million. We recognized a loss on extinguishment of debt totaling $8.8 million in the first quarter of 2020.

We also have senior unsecured notes outstanding of $350.0 million due November 15, 2022 (at a stated interest rate of 3.75%), $400.0 million due December 1, 2024 (at a stated interest rate of 3.5%) and $600.0 million due December 1, 2027 (at a stated interest rate of 3.75%) that are rated BBB by Standard & Poor’s and Baa2 by Moody’s.

Revolving Credit Facility (the "Facility")

On February 5, 2020, the Company entered into the Company's Fourth Amended and Restated Credit Agreement (the “Amendment”) administered by JPMorgan Chase Bank, N.A. Among other things, the Amendment extended the maturity date of the Facility from February 21, 2022, to February 5, 2025.

During the nine months ended September 30, 2020, borrowings under the Facility totaled $500.0 million with a weighted average interest rate of 1.9%, and repayments totaled $500.0 million. As of September 30, 2020, there were no borrowings under the Facility and $1.0 billion of availability. During the year ended and as of December 31, 2019 there were no borrowings under the Facility.

Debt Covenants

We are required to meet various restrictive covenants and limitations under our senior notes and revolving credit facility including certain leverage ratios, interest coverage ratios and limits on outstanding debt balances held by certain subsidiaries. We were in compliance with all covenants and limitations as of September 30, 2020 and December 31, 2019.

Refer to Note 12 for further information on our debt instruments.

New Accounting Pronouncements

Refer to Note 2 for more information regarding new accounting pronouncements.

Critical Accounting Estimates

Our significant accounting policies are more fully described in Note 1 to our Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Annual Report on Form 10-K"). In preparing the Consolidated Financial Statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company’s management must make informed decisions which impact the reported amounts and related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and assumptions on which to base estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to revenue recognition, extended product warranties, goodwill and indefinite-lived intangible assets, valuation of long-lived assets, and income taxes on an ongoing basis. The Company bases its estimates on historical experience, terms of existing contracts, our observation of trends in the industry, information provided by our customers and information available from other outside sources, that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. There have been no material changes to our accounting policies and estimates as described in the 2019 Annual Report on Form 10-K, except as noted below.

Subsequent Measurement of Goodwill

Goodwill is not amortized but is tested annually, or more often if impairment indicators are present, for impairment at a reporting unit level, based on a comparison of the fair value of the reporting unit with its carrying amount. Goodwill is tested for impairment via a one-step process by comparing the fair value of goodwill with its carrying amount. We recognize an impairment for the amount by which the carrying amount exceeds the fair value. We generally use both an income approach utilizing the discounted cash flow method ("DCF") and a market approach utilizing the public company market multiple method, when testing for impairment. The key techniques and assumptions used include:

Valuation Technique Key Assumptions
Discounted future cash flows •Estimated future revenues •Earnings before interest, taxes, depreciation and amortization ("EBITDA") margins •Discount rates
Market multiple method •Peer public company group •Financial performance of reporting units relative to peer public company group

In the second quarter of 2020, changes in facts and circumstances and general market declines from COVID-19 resulted in reduced operating results. We considered these circumstances and the potential long-term impact on cash flows associated with our reporting units and determined that an indicator of possible impairment existed within our CFT and CBF reporting units. Accordingly, we tested our goodwill for impairment as of June 30, 2020. Those reporting units were tested for impairment using the quantitative approach described above, resulting in a fair value for the CFT reporting unit that exceeded the carrying amount by approximately 10 percent, and a fair value for the CBF reporting unit that substantially exceeded the carrying amount. The carrying amount of goodwill for the CFT and CBF reporting units was $186.2 million and $96.4 million, respectively, as of June 30, 2020. No triggering events were identified in the third quarter of 2020, accordingly no further goodwill impairment tests were performed.

We will continue to closely monitor actual results versus expectations as well as whether and to what extent any significant changes in current events or conditions, including changes to the impacts of COVID-19 on our business, result in corresponding changes to our expectations about future estimated cash flows, the weighted average cost of capital ("WACC") and market multiples. If our adjusted expectations of the operating results, both in size and timing, of CFT and CBF do not materialize, if the WACC increases (based on increases in interest rates, market rates of return or market volatility) or if market multiples decline, we may be required to record goodwill impairment charges, which may be material.

While we believe our conclusions regarding the estimates of fair value of our reporting units are appropriate, these estimates are subject to uncertainty and by nature include judgments and estimates regarding various factors. These factors include the rate and extent of growth in the markets that our reporting units serve, the realization of future sales price and volume increases, fluctuations in exchange rates, fluctuations in price and availability of key raw materials, future operating efficiencies and, as it pertains to discount rates, the volatility in interest rates and costs of equity.

Refer to Note 11 for more information regarding goodwill.

Subsequent Measurement of Indefinite-Lived Intangible Assets

As discussed above, indefinite-lived intangible assets are recognized and recorded at their acquisition-date fair value. Intangible assets with indefinite useful lives are not amortized but are tested annually at the appropriate unit of account, which generally equals the individual asset, or more often if impairment indicators are present. Indefinite-lived intangible assets are tested for impairment via a one-step process by comparing the fair value of the intangible asset with its carrying amount. We recognize an impairment charge for the amount by which the carrying amount exceeds the intangible asset's fair value. We generally estimate the fair value of our indefinite-lived intangible assets consistent with the techniques noted above using our expectations about future cash flows, discount rates and royalty rates for purposes of the annual test. We monitor for significant changes in those assumptions during interim reporting periods. We also periodically re-assess indefinite-lived intangible assets as to whether its useful lives can be determined, and if so, we would begin amortizing any applicable intangible asset.

In the second quarter of 2020, changes in facts and circumstances and general market declines from COVID-19 resulted in reduced revenues. We considered these circumstances and the potential long-term impact on revenues associated with its indefinite-lived trade names and determined that an indicator of possible impairment existed. Accordingly, we performed a quantitative impairment analysis to determine the fair values of our CFT and CBF indefinite-lived trade names using the method described above.

Based on the output of the analysis, we determined that the fair value of one CFT trade name with a carrying value of $39.0 million exceeded the carrying amount by less than 10 percent. The remaining CFT and CBF indefinite-lived trade names substantially exceeded their carrying amounts. Accordingly, no impairment charges were required as of June 30, 2020. The carrying amount of indefinite-lived trade names for CFT and CBF were $129.1 million and $42.0 million, respectively, as of June 30, 2020. No triggering events were identified in the third quarter of 2020, accordingly no further intangible asset impairment tests were performed.

We will continue to closely monitor actual results versus expectations as well as whether and to what extent any significant changes in current events or conditions, including changes to the impacts of COVID-19 on our business, result in corresponding changes to our expectations about future estimated revenues and the weighted average cost of capital. If our adjusted expectations of the revenues, both in size and timing, of CFT and CBF trade names do not materialize or if the WACC increases (based on increases in interest rates, market rates of return or market volatility), we may be required to record trade name impairment charges, which may be material.

Refer to Note 11 for more information regarding intangible assets.

Items Affecting Comparability

Items affecting comparability include costs, and losses or gains related to, among other things, growth and profitability improvement initiatives and other events outside of core business operations (such as asset impairments, exit and disposal and facility rationalization charges, costs of and related to acquisitions, litigation settlement costs, gains and losses from and costs related to divestitures, idle capacity and labor costs, net of subsidies, losses on debt extinguishment and discrete tax items). Because these items affect our, or any particular operating segment's, financial condition or results in a specific period in which they are recognized, we believe it is appropriate to present the total of these items to provide information regarding the comparability of results of operations period to period. The components of items affecting comparability follows:

(in millions, except per share amounts)

Three Months Ended September 30, 2020 Impact to Operating Income Impact to Income from Continuing Operations Impact to Diluted EPS from Continuing Operations Three Months Ended September 30, 2019 Impact to Operating Income Impact to Income from Continuing Operations Impact to Diluted EPS from Continuing Operations
Exit and disposal costs $5.5 $4.2 $0.08 $1.8 $1.3 $0.02
Other facility rationalization costs 0.1 0.1 — 1.2 0.9 0.02
Acquisition related costs:
Inventory step-up amortization 0.2 0.1 — 1.0 0.8 0.01
Other acquisition costs 0.3 0.2 — 3.4 2.6 0.05
Idle capacity and labor costs, net of subsidies 0.2 0.2 — — — —
Losses from divestitures — — — — 0.5 0.01
Discrete tax items(1) — (0.8) (0.01) — (2.2) (0.04)
Total items affecting comparability $6.3 $4.0 $0.07 $7.4 $3.9 $0.07

(1) In order to provide better information to the user, items affecting comparability include all discrete tax items in this period and all comparative periods.

(in millions, except per share amounts)

Nine Months Ended September 30, 2020 Impact to Operating Income Impact to Income from Continuing Operations Impact to Diluted EPS from Continuing Operations Nine Months Ended September 30, 2019 Impact to Operating Income Impact to Income from Continuing Operations Impact to Diluted EPS from Continuing Operations
Exit and disposal costs $18.6 $14.1 $0.25 $10.1 $7.6 $0.13
Other facility rationalization costs 2.0 1.5 0.03 3.5 2.7 0.05
Acquisition related costs:
Inventory step-up amortization 0.4 0.3 — 2.2 1.7 0.03
Other acquisition costs 5.7 4.3 0.08 6.3 4.8 0.08
Idle capacity and labor costs, net of subsidies 8.0 6.0 0.11 — — —
Gain from contingent consideration — — — (3.0) (3.0) (0.05)
Gain from step acquisition, net — — — — (0.3) —
(Gains) losses from divestitures (0.8) (0.6) (0.01) — 0.5 0.01
Loss on debt extinguishment — 6.6 0.12 — — —
Indemnification losses — 3.1 0.05 — — —
Discrete tax items(1) — (6.2) (2) (0.11) — (7.2) (0.13)
Total items affecting comparability $33.9 $29.1 $0.52 $19.1 $6.8 $0.12

(1) In order to provide better information to the user, items affecting comparability include all discrete tax items in this period and all comparative periods.

(2) Excludes $0.1 million of discrete tax items related to indemnification asset write-offs which had zero impact to income from continuing operations and EPS from continuing operations.

The impact to income from continuing operations reflects the tax effect of items affecting comparability based on the statutory rate in the jurisdiction in which the expense or income is deductible or taxable. The per share impact of items affecting comparability to each period is based on diluted shares outstanding using the two-class method (refer to Note 5).

Outlook

Our expectations for segment revenues in the fourth quarter of 2020, compared to the fourth quarter of 2019 follows:

Fourth-quarter 2020 Revenue
Carlisle Construction Materials Low-single digit growth
Carlisle Interconnect Technologies Decline mid-30%
Carlisle Fluid Technologies Decline mid-teens
Carlisle Brake & Friction Decline low-single digits
Total Carlisle Decline high-single digits

For the year 2020, we expect:

  • Corporate expenses of approximately $95 million;
  • Depreciation and amortization expense of approximately $230 million;
  • Capital expenditures between $100 million and $110 million;
  • Net interest expense of approximately $75 million; and
  • Tax rate of approximately 23%.

In response to declining demand attributable to COVID-19, we may make selected adjustments to our expectations noted above.

Forward-Looking Statements

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential or expected impacts of the global COVID-19 pandemic. Forward-looking statements generally use words such as "expect," "foresee," "anticipate," "believe," "project," "should," "estimate," "will," "plans," "intends," "forecast," and similar expressions, and reflect our expectations concerning the future. Such statements are made based on known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties. It is possible that our future performance may differ materially from current expectations expressed in these forward-looking statements, due to a variety of factors such as: risks from the global COVID-19 pandemic, including, for example, expectations regarding the impact of COVID-19 on our businesses, including on customer demand, supply chains and distribution systems, production, our ability to maintain appropriate labor levels, our ability to ship products to our customers, our ability to obtain financial and tax benefits from the recently-passed CARES Act, our future results, or our full-year financial outlook; increasing price and product/service competition by foreign and domestic competitors, including new entrants; technological developments and changes; the ability to continue to introduce competitive new products and services on a timely, cost-effective basis; our mix of products/services; increases in raw material costs which cannot be recovered in product pricing; domestic and foreign governmental and public policy changes including environmental and industry regulations; threats associated with and efforts to combat terrorism; protection and validity of patent and other intellectual property rights; the identification of strategic acquisition targets and our successful completion of any transaction and integration of our strategic acquisitions; the cyclical nature of our businesses; and the outcome of pending and future litigation and governmental proceedings; and the other factors discussed in the reports we file with or furnish to the Securities and Exchange Commission ("SEC") from time to time. In addition, such statements could be affected by general industry and market conditions and growth rates, the condition of the financial and credit markets and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. Further, any conflict in the international arena may adversely affect general market conditions and our future performance. Any forward-looking statement speaks only as of the date on which that statement is made, and we undertake no duty to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date on which that statement is made, unless otherwise required by law. New factors emerge from time to time and it is not possible for management to predict all of those factors, nor can it assess the impact of each of those factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

Market risk

As filed, 275 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in the Company’s market risk for the nine months ended September 30, 2020. For additional information, refer to "PART II—Item 7A. Quantitative and Qualitative Disclosures About Market Risk" of the Company’s 2019 Annual Report on Form 10-K.

Controls and procedures

As filed, 864 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

a. Evaluation of disclosure controls and procedures. Under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation and as of September 30, 2020, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective.

b. Changes in internal controls. During the first nine months of 2020, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Risk factors

As filed, 2,268 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as noted below, there have been no material changes in the Company's risk factors disclosed in "PART I—Item 1A. Risk Factors" in our 2019 Annual Report on Form 10-K.

The Company is subject to risks arising from global pandemics including the coronavirus pandemic ("COVID-19").

The Company’s businesses operate in market segments currently being impacted by the COVID-19 pandemic. Operating during a global pandemic exposes the Company to a number of risks, including diminished demand for our products and our customers’ products, suspensions in the operations of our manufacturing facilities, maintenance of appropriate labor levels and our ability to ship products to our customers, interruptions in our supply chains and distribution systems, increases in operating costs related to pay and benefits for our employees, collection of trade receivables in accordance with their terms, potential impairment of goodwill and long-lived assets; all of which, in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.

We have experienced, and expect to continue to experience, diminished demand for our products as a result of COVID-19. The decline in domestic and international passenger airline travel caused by COVID-19 is negatively impacting demand for our products sold to customers operating in the commercial aerospace industry. COVID-19 related delays in nonresidential replacement starts in certain regions are negatively impacting demand for our products sold to customers operating in the nonresidential construction materials industry. While these COVID-19 related impacts have not to date, in the aggregate, had a material adverse impact on the Company, we are unable to predict the extent or duration of these impacts as they will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the duration of the coronavirus outbreak, the timing and extent of increased passenger airline travel and nonresidential construction and construction repair and replacement activity, and the continued ability of our businesses to continue to operate within all applicable COVID-19 related government rules and regulations.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$1.13bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$3.18bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$796.4mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-01-01 to 2020-09-30$2.29bnus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2020-07-01 to 2020-09-30$13.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$42.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-07-01 to 2020-09-30$162.3mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$477.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30$155.7mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30$371.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$19.0mus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$57.7mus-gaap:InterestExpense
Income tax3 months2020-07-01 to 2020-09-30$34.1mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-30$70.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30$102.3mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30$239.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-07-01 to 2020-09-30$1.87us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30$4.31us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-07-01 to 2020-09-30$1.88us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-30$4.35us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-07-01 to 2020-09-3054,500,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-3055,400,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-30$440.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$72.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2020-01-01 to 2020-09-30$84.5mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2020-01-01 to 2020-09-30$341.7mus-gaap:PaymentsForRepurchaseOfCommonStock
Current assetsAt period end2020-09-30$2.14bnus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$5.80bnus-gaap:Assets
Current liabilitiesAt period end2020-09-30$645.7mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-09-30$2.08bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-09-30$900.0kus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2020-09-30$2.48bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000790051-20-000130. Last ingested by Listed: Nov 10, 2026, 16:42 ET. Listed shows no prices and gives no investment advice.